RIGL
NASDAQ · Biotechnology
Rigel Pharmaceuticals Inc
$25.96
-0.14 (-0.54%)
Financial Highlights (FY 2026)
Revenue
184.14M
Net Income
17.96M
Gross Margin
89.6%
Profit Margin
9.8%
Rev Growth
+6.3%
D/E Ratio
18.15
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 89.6% | 89.6% | 39.5% | 39.5% |
| Operating Margin | 13.5% | 12.1% | -16.5% | -15.8% |
| Profit Margin | 9.8% | 9.3% | -16.5% | -20.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 184.14M | 173.21M | 385.25M | 314.84M |
| Gross Profit | 164.99M | 155.19M | 152.10M | 124.30M |
| Operating Income | 24.84M | 21.03M | -63,385,649 | -49,763,269 |
| Net Income | 17.96M | 15.20M | -63,461,041 | -63,887,744 |
| Gross Margin | 89.6% | 89.6% | 39.5% | 39.5% |
| Operating Margin | 13.5% | 12.1% | -16.5% | -15.8% |
| Profit Margin | 9.8% | 9.3% | -16.5% | -20.3% |
| Rev Growth | +6.3% | +6.3% | +12.7% | +12.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 313.02M | 313.02M | 244.43M | 243.77M |
| Total Equity | 17.25M | 17.25M | 293.70M | 288.30M |
| D/E Ratio | 18.15 | 18.15 | 0.83 | 0.85 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 27.14M | 24.25M | -108,813,206 | -86,400,635 |
| Free Cash Flow | — | — | -71,858,369 | -72,598,863 |